Results 111 to 120 of about 1,093,896 (249)
Characteristics of eligible studies utilizing Janus kinase inhibitors for the cicatricial alopecia treatment.
Azadeh Goodarzi (3433010) +3 more
core +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva +17 more
wiley +1 more source
From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatment
Frontiers in MedicineJanus kinase inhibitors have emerged as highly effective therapies, gaining a prominent role in rheumatoid arthritis treatment. However, by inhibiting multiple cytokine effector pathways, these agents have also raised concerns regarding their safety ...
Karina R. Bonfiglioli
doaj +1 more source
JEADV Clinical Practice, EarlyView.Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella +3 more
wiley +1 more source
SAGE Open Medical Case ReportsThis case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient.
Barbara Marzario +2 more
doaj +1 more source
Advancing therapeutic frontiers: a pipeline of novel drugs for UC management
Frontiers in GastroenterologyUlcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin +9 more
doaj +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Vaccarin is a naturally occurring flavonoid glycoside with cardioprotective properties; however, its involvement in myocardial ischemia–reperfusion (MI/R) injury remains poorly defined. We herein investigated whether vaccarin protects cardiomyocytes from MI/R‐induced dysfunction in vivo and in vitro and examined the associated molecular ...
Han Yang, Mi Zhou, Feng‐Cai Zhang
wiley +1 more source
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Psoriasis: Targets and Therapy, 2019 Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K +4 more
doaj
Supplemental Tables 1-3 for "Janus kinase inhibitors combined with 308-nm excimer laser for vitiligo: A systematic ...
Bai, Jia Qi Adam
core +1 more source
An atypical mycobacterial infection while on Janus kinase inhibitor therapy [PDF]
Janus kinase inhibitors are immunomodulatory drugs increasingly used to treat a broad range of inflammatory dermatologic conditions. Although effective, they carry a risk of serious adverse effects, including opportunistic infections.
Rogge, Megan N +3 more
core +1 more source